Literature DB >> 1373879

Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.

M Jücker1, A J Roebroek, J Mautner, K Koch, D Eick, V Diehl, W J Van de Ven, H Tesch.   

Abstract

The human c-fps/fes proto-oncogene is expressed as a transcript of about 3.0 kb in both normal and leukemic myeloid cells. We have detected truncated c-fps/fes transcripts of about 0.9 kb in a panel of human lymphoma and lymphoid leukemia cell lines, but not in normal untransformed hematopoietic cells. Analysis of the chromatin structure of the c-fps/fes gene revealed DNAase I-hypersensitive sites in the 5' region of the gene and in exon 16. The presence and absence of these sites correlates with the expression of the 3.0 kb and 0.9 kb c-fps/fes RNAs respectively. The truncated transcripts initiate at two distinct sites within exon 16 of the c-fps/fes gene. The genomic region 5' to the transcription initiation sites is G+C rich but does not contain typical promoter consensus sequences. Sequence analysis of a cDNA clone of the truncated c-fps/fes transcripts did not reveal any point mutation and the truncated transcripts are normally spliced using the regular splice donor and acceptor sites. A putative open reading frame encompasses the phosphotransfer motif and the autophosphorylation site of the fps/fes kinase domain. In vitro transcription/translation of a cDNA clone corresponding to the truncated c-fps/fes transcripts revealed a protein of 17 kDa. There are no translocations or rearrangements in or around the c-fps/fes gene in cell lines which express the truncated c-fps/fes transcripts. This alternative transcription of c-fps/fes may indicate a novel activation process of this proto-oncogene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373879

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor.

Authors:  A Heydemann; G Juang; K Hennessy; M S Parmacek; M C Simon
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  Nucleosomal structures of c-myc promoters with transcriptionally engaged RNA polymerase II.

Authors:  T Albert; J Mautner; J O Funk; K Hörtnagel; A Pullner; D Eick
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

3.  Microsatellite instability in IVS3 of murine c-fes gene: tumor-associated rearrangement and mammalian divergence.

Authors:  L Volpi; A Beghini; D Rossi; L Larizza
Journal:  Mamm Genome       Date:  1996-09       Impact factor: 2.957

4.  Identification of two enhancer elements downstream of the human c-myc gene.

Authors:  J Mautner; S Joos; T Werner; D Eick; G W Bornkamm; A Polack
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

5.  Comprehensive analysis of the genome transcriptome and proteome landscapes of three tumor cell lines.

Authors:  Pelin Akan; Andrey Alexeyenko; Paul Igor Costea; Lilia Hedberg; Beata Werne Solnestam; Sverker Lundin; Jimmie Hällman; Emma Lundberg; Mathias Uhlén; Joakim Lundeberg
Journal:  Genome Med       Date:  2012-11-18       Impact factor: 11.117

6.  ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK.

Authors:  Yuval Yung; Zhong Yao; Tamar Hanoch; Rony Seger
Journal:  Cell Biol Int       Date:  2022-04-04       Impact factor: 4.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.